Dai ichi Life Insurance Company Ltd Lowers Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dai ichi Life Insurance Company Ltd trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 28.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,244 shares of the company’s stock after selling 14,902 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Teva Pharmaceutical Industries were worth $671,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in Teva Pharmaceutical Industries by 5.9% in the third quarter. The Manufacturers Life Insurance Company now owns 432,402 shares of the company’s stock valued at $7,792,000 after acquiring an additional 24,248 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 89,465 shares of the company’s stock worth $1,612,000 after purchasing an additional 8,100 shares in the last quarter. Centaurus Financial Inc. grew its position in Teva Pharmaceutical Industries by 27.7% during the 3rd quarter. Centaurus Financial Inc. now owns 17,891 shares of the company’s stock worth $322,000 after purchasing an additional 3,876 shares during the last quarter. Okabena Investment Services Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $1,059,000. Finally, Pitcairn Co. acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $947,000. Institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TEVA. Barclays raised their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of TEVA opened at $16.57 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The firm has a market cap of $18.77 billion, a P/E ratio of -19.49, a PEG ratio of 1.30 and a beta of 0.87. The stock’s 50 day moving average is $17.57 and its two-hundred day moving average is $17.35. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.